FY2024 EPS Estimates for Immatics (NASDAQ:IMTX) Increased by Cantor Fitzgerald

Immatics (NASDAQ:IMTX) – Stock analysts at Cantor Fitzgerald lifted their FY2024 earnings estimates for Immatics in a research report issued to clients and investors on Wednesday, August 14th. Cantor Fitzgerald analyst E. Schmidt now anticipates that the company will earn ($0.80) per share for the year, up from their prior estimate of ($0.85). The consensus estimate for Immatics’ current full-year earnings is ($1.25) per share.

Separately, Mizuho raised their price objective on Immatics from $14.00 to $16.00 and gave the stock a “buy” rating in a research report on Thursday, May 16th.

Immatics Stock Down 0.3 %

IMTX stock opened at $11.75 on Monday. Immatics has a twelve month low of $7.15 and a twelve month high of $13.77. The company has a market cap of $994.73 million, a PE ratio of -11.08 and a beta of 0.75. The business’s 50-day simple moving average is $12.07 and its 200 day simple moving average is $11.60.

Institutional Investors Weigh In On Immatics

Several institutional investors and hedge funds have recently bought and sold shares of IMTX. Trexquant Investment LP lifted its holdings in shares of Immatics by 4.2% during the 4th quarter. Trexquant Investment LP now owns 44,773 shares of the company’s stock worth $471,000 after acquiring an additional 1,801 shares during the period. AlphaCentric Advisors LLC lifted its stake in Immatics by 14.3% during the second quarter. AlphaCentric Advisors LLC now owns 20,000 shares of the company’s stock worth $232,000 after purchasing an additional 2,500 shares during the period. Jump Financial LLC lifted its stake in Immatics by 19.8% during the fourth quarter. Jump Financial LLC now owns 48,484 shares of the company’s stock worth $511,000 after purchasing an additional 8,014 shares during the period. Quarry LP acquired a new stake in Immatics during the second quarter valued at approximately $99,000. Finally, Forefront Analytics LLC bought a new stake in shares of Immatics in the 2nd quarter valued at approximately $139,000. Institutional investors own 64.41% of the company’s stock.

About Immatics

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics.